Semaglutide in Heart Failure With Preserved Ejection Fraction: Exploring Recent Evidence in Therapeutic Potential for the Obese Population.
| Autor: | Kusayev J; From the Department of Medicine, New York Medical College, Valhalla, NY., Levy Y; From the Department of Medicine, New York Medical College, Valhalla, NY., Weininger D; Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY., Frishman WH; From the Department of Medicine, New York Medical College, Valhalla, NY., Aronow WS; Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cardiology in review [Cardiol Rev] 2024 May 17. Date of Electronic Publication: 2024 May 17. |
| DOI: | 10.1097/CRD.0000000000000726 |
| Abstrakt: | Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent condition, particularly among the aging population in the United States, and is associated with significant challenges due to its complex pathophysiology and limited therapeutic options. Historically, few pharmacological therapies have successfully mitigated HFpEF, making the emergence of effective treatments particularly significant. This review evaluates recent evidence on the therapeutic potential of semaglutide for managing HFpEF, especially in the obese population. Results from the STEP-HFpEF and STEP-HFpEF DM trials demonstrate that semaglutide, a glucagon-like peptide-1 receptor agonist originally developed for type 2 diabetes but now also approved for obesity treatment, significantly improves clinical outcomes such as symptom scores, body weight, exercise capacity, and inflammation markers in the obese population suffering from HFpEF. These improvements are attributed to both the weight loss induced by semaglutide and its direct effects on the congestive pathophysiology of HFpEF. The efficacy of semaglutide offers new hope for addressing a condition that has long lacked effective pharmacological interventions. Competing Interests: Disclosure: The authors declare no conflict of interest. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|